Bill Explanation

Bill Explanation

H.R. 3520 is a bill introduced in the House of Representatives by Mr. S MITH of New Jersey and Mr. BILIRAKIS. This bill aims to reauthorize the Stem Cell Therapeutic and Research Act of 2005 and make a few other changes.

Short Title

This bill may also be referred to as the "Stem Cell Therapeutic and Research Reauthorization Act of 2019."

Reauthorization of the C.W. Bill Young Cell Transplantation Program

Section 379(d)(2)(B) of the Public Health Service Act (42 U.S.C. 274k(d)(2)(B)) is being amended by this bill. The amendment changes the language related to the collection of stem cells to be consistent with the inventory. The bill also adds remote collection as a method of collecting stem cells, as long as it meets the necessary requirements.

Advisory Council Meetings

This bill requires the Secretary to convene the Advisory Council at least two times each calendar year. The Advisory Council is a group that provides advice and recommendations regarding stem cell transplantation.

Authorization of Appropriations

Section 379B of the Public Health Service Act is being amended to change the authorized appropriations. The bill reduces the funding from $33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal years 2016 through 2020 to $30,000,000 for each of fiscal years 2020 through 2024.

Cord Blood Inventory

The Stem Cell Therapeutic and Research Act of 2005 is also being amended in relation to the cord blood inventory. The bill authorizes $23,000,000 for each of fiscal years 2020 through 2024 to carry out this section of the Act.

HB 3520 Stem Cell Therapeutic and Research Reauthorization Act of 2019

US Congress 116th Congress

Bill Texts

Introduced 07/09/2019

Weigh In

Spread the Word!

Sponsors (4)

Rep. Gus Bilirakis

Co-Sponsor

Rep. Christopher Smith

Primary Sponsor

Rep. Blaine Luetkemeyer

Co-Sponsor

Rep. Cindy Axne

Co-Sponsor